Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14760611 | 0.76 | CTSL (0.42) | POLBKDM4EKMT2AATMALDH1A1 | |
| SCHEMBL2293796 | 0.70 | POLB (0.54) | POLBKDM4EKMT2AATMALDH1A1 | |
| SCHEMBL19249449 | 0.67 | POLB (0.37) | POLBKDM4EKMT2AATMALDH1A1 | |
| SCHEMBL254096 | 0.67 | KMT2A (0.40) | POLBKDM4EKMT2AALDH1A1MAPK1 | |
| SCHEMBL11206485 | 0.67 | POLB (0.37) | POLBKDM4EKMT2AATMALDH1A1 | |
| SCHEMBL1374885 | 0.67 | POLB (0.41) | POLBKDM4EKMT2AATMALDH1A1 | |
| SCHEMBL19286550 | 0.67 | KMT2A (0.38) | POLBKDM4EKMT2AALDH1A1NPC1 | |
| SCHEMBL25035461 | 0.67 | POLB (0.38) | POLBKDM4EKMT2AATMALDH1A1 | |
| SCHEMBL12706319 | 0.67 | POLB (0.40) | POLBKDM4EKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13246807 | 0.67 | POLB (0.38) | POLBKDM4EKMT2AATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | claimed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | claimed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | POLB 3665/4885KDM4E 2318/4885KMT2A 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.